Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Resistance to Targeted Therapies in Lymphomas / / edited by Ana C. Xavier, Mitchell S. Cairo
| Resistance to Targeted Therapies in Lymphomas / / edited by Ana C. Xavier, Mitchell S. Cairo |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (XX, 210 p. 27 illus., 26 illus. in color.) |
| Disciplina |
614.5999
616.99446 |
| Collana | Resistance to Targeted Anti-Cancer Therapeutics |
| Soggetto topico |
Lymphomas - Treatment
Drug resistance Lymphoma - therapy Molecular Targeted Therapy Drug Resistance, Neoplasm |
| ISBN | 3-030-24424-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies -- Resistance to Monoclonal Antibody Therapeutics in Lymphoma -- Resistance to Antibody-Drug Conjugate -- Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma -- Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma -- Resistance to Bruton’s Tyrosine Kinase Signaling Pathway Targeted Therapies -- Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs -- Resistance to Bispecific T-cell Engagers and Bispecific Antibodies -- Resistance to Chimeric antigen receptor T-cell therapy -- Index. |
| Record Nr. | UNINA-9910349443803321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Targeting oncogenic drivers and signaling pathways in lymphoid malignancies : from concept to practice / / edited by Owen A. O'Connor, Stephen Ansell, and John Seymour
| Targeting oncogenic drivers and signaling pathways in lymphoid malignancies : from concept to practice / / edited by Owen A. O'Connor, Stephen Ansell, and John Seymour |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2023] |
| Descrizione fisica | 1 online resource (514 pages) |
| Disciplina | 616.99406 |
| Collana | Precision cancer therapies |
| Soggetto topico |
Cancer - Treatment
Precision Medicine Lymphoma - therapy Signal Transduction |
| ISBN |
1-119-81995-4
1-119-81993-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Precision Cancer Therapies -- Contents -- List of Contributors -- Volume Foreword -- Volume Preface -- Series Preface -- Section I Biological Basis of the Lymphoid Malignancies -- 1 Fundamental Principles of Lymphomagenesis -- Take Home Messages -- Introduction -- How to Study Lymphomagenesis -- Before Lymphoma: The Gray Frontier Between Physiology and Pathology -- Driver Without Disease -- From In Situ Neoplasms to Asymptomatic Lymphomas -- Chronic Antigenic Stimulation as an Early Step of Lymphomagenesis -- The Cell of Origin Concept: A Classification Based on Physiology -- What Are the Hallmarks of Lymphoma? -- Epigenetics and Metabolism -- Apoptosis Escape -- Proliferation -- TCR/BCR Signaling -- Immune Escape -- Trafficking -- Microenvironment -- Conclusion -- Must Read References -- References -- 2 Identifying Molecular Drivers of Lymphomagenesis -- Take Home Messages -- Introduction -- Sequencing and Bioinformatics Methods -- Functional Validation of Drivers -- Common Themes in B- and T-cell Lymphoma -- Genetic Landscapes of Lymphomas -- Mature B-cell Lymphomas -- T-cell Lymphomas -- Genomic Subgrouping Approaches in DLBCL -- Challenges of Incorporating Genomic Subgrouping Approaches in Clinical Trials -- Leveraging Underlying Pathophysiology to Inform Therapeutic Consideration -- Conclusion -- Must Read References -- References -- 3 Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies -- Take Home Messages -- Introduction: Epigenetics and Lymphoid Malignancies -- Dysregulation of DNA Methylation and Modification of Histone Proteins -- Genes Involved in Histone Modification Implicated in Lymphomagenesis -- Enhancer of Zeste Homolog 2 (EZH2) -- CREB-binding Protein (CREBBP) and Histone Acetyltransferase P300 (EP300) -- The H3K4 Methyltransferase Family.
The Bromodomain and Extra-Terminal Domain (BET) Family -- Genes Involved in DNA Methylation Implicated in Lymphomagenesis -- DNA Methyltransferase 3A (DNMT3A) -- Ten-Eleven Translocation 1/2 (TET1/2) -- Isocitrate Dehydrogenase 2 (IDH2) -- The Epigenetic Landscape of Specific Lymphoid Malignancies -- Follicular Lymphoma -- Diffuse Large B-cell Lymphoma -- Marginal Zone Lymphoma -- Burkitt's Lymphoma -- Acute Lymphoblastic Leukemia -- Chronic Lymphocytic Leukemia -- Mantle Cell Lymphoma -- Hodgkin's Lymphoma -- Multiple Myeloma -- Peripheral T-cell Lymphoma - Not Otherwise Specified -- Angioimmunoblastic T-cell Lymphoma and PTCL with TFH Phenotype -- Anaplastic Large Cell Lymphoma -- Adult T-cell Leukemia/Lymphoma -- Intestinal T-cell Lymphoma -- Hepatosplenic T-cell Lymphomas -- NK/T Cell Lymphoma -- Mycosis Fungoides and Sezary's Syndrome -- Summary -- Must Read References -- References -- 4 Animal Models of Lymphoid Malignancies -- Take Home Messages -- Introduction -- Optimal Animal Models to Study Lymphoid Neoplasms -- Zebrafish Model -- Zebrafish Model of T-cell Neoplasms -- Zebrafish Model of B-cell Neoplasms -- Zebrafish Model of NK-cell Neoplasms -- Patient-Derived Xenograft Models in Zebrafish -- Fruit Fly Model -- Non-human Primate Model -- Mouse Models of Lymphoid Neoplasia -- Use of Animal Models in Translational Research -- Conclusions -- Must Read References -- References -- Section II Targeting the PI3 Kinase-AKT-mTOR Pathway -- 5 Principles of PI3K Biology and Its Role in Lymphoma -- Take Home Messages -- Introduction: Overview -- Four Decades of PI3K Signaling Research -- Class I PI3K Enzymes -- Isoforms -- Structural Organization -- Isoform-specific Functions -- The Essential Phospholipid Second Messenger PIP3 -- PI3K Pathway Effectors -- AKT, FOXO, and mTORC1 -- TEC Tyrosine Kinases -- Network Topology and Signal Robustness. Dynamic PI3K Signaling in Lymphocyte Biology -- B-cell Development and Survival -- The Germinal Center (GC) Reaction -- TFH Cell Function -- Naïve and Effector T-cells -- Lessons from Monogenic Disorders -- Genetic PI3Kd Inactivation -- Genetic PI3Kd Hyperactivation -- Corrupted PI3K Signaling in Cancer -- The Success of PI3Kd Inhibition in Lymphoid Malignancies -- Quantitative Biology and Therapeutic Considerations -- Concluding Remarks -- Acknowledgments -- Must Read Reference -- References -- 6 Pharmacologic Differentiation of Drugs Targeting the PI3K-AKT-mTOR Signaling Pathway -- Take Home Messages -- Introduction -- PI3K Inhibitors Approved by the US Food and Drug Administration (FDA) -- PI3K Inhibitors in Clinical Development -- AKT Inhibitors -- mTOR Inhibitors -- Conclusions -- Must Read References -- References -- 7 Clinical Experience with Phosphatidylinositol 3-Kinase Inhibitors in Hematologic Malignancies -- Take Home Messages -- Introduction -- Idelalisib -- Copanlisib -- Duvelisib -- Umbralisib -- Parsaclisib -- Zandelisib -- Amdizalisib (HMPL-689) -- Conclusion -- Must Read References -- References -- 8 Clinical Experiences with Drugs Targeting mTOR -- Take Home Messages -- Introduction -- Rapamycin (Sirolimus) Rapamune® (Pfizer) and Generic Sirolimus -- The Rapamycin Analogs (Rapalogs) -- Temsirolimus (CCI-779 -- Torisel) -- Everolimus (RAD-001 -- Afinitor, Zortrees, Evertor) -- Summary of Lymphoma Studies of Everolimus -- Ridaforolimus -- Dual Inhibitors of mTORC1 and mTORC2 -- Side Effects of mTORC1 Inhibitors -- Future Directions for mTOR Inhibitors in Lymphoma -- Must Read References -- References -- 9 PI3 Kinase, AKT, and mTOR Inhibitors -- Take Home Messages -- Introduction -- PI3K Structure and Functions -- AKT Structure and Functions -- mTOR Structure and Functions -- PTEN as a Regulator of the PI3K/AKT/mTOR Pathway. mTOR Inhibitors -- Temsirolimus: Phase 3 Trials -- PI3K and Dual PI3K/mTOR Inhibitors -- PI3K Isoforms and Expression Throughout the Body -- Immune Toxicity and Management -- Colitis -- Hepatitis -- Pneumonitis -- Skin Rash -- Homeostatic Toxicity -- Hypertension and Hyperglycemia -- Myelosuppression and Opportunistic Infection -- Myelosuppression -- Atypical Infection -- Vaccination -- Neuropsychiatric Problems -- PI3K Treatment in NHL -- AKT Inhibitors -- Conclusion -- Must Read References -- References -- Section III Targeting Programmed Cell Death -- 10 Principles for Understanding Mechanisms of Cell Death and Their Role in Cancer Biology -- Take Home Messages -- Introduction -- A Historical Perspective -- Apoptotic Pathways -- Other Cell Death Pathways -- The Role of Intrinsic Apoptosis in Normal Cells - Lessons from Gene Knockout Mice -- BCL2 Family Pro-survival Proteins -- BCL2 -- BCL-XL -- MCL-1 -- A1/BFL-1 -- BCL-W -- Combined Knockout of Pro-survival Proteins -- BCL2 Family Pro-apoptotic Effector Proteins -- BH3-only Proteins -- The Dysregulation of Apoptosis in Cancer -- Must Read References -- References -- 11 Pharmacologic Features of Drugs Targeting BCL2 Family Members -- Take Home Messages -- Introduction -- Historical Perspective: From the Discovery of BCL2 to Therapeutic Applications -- BCL2 as a Biomarker -- Targeting BCL2 Family Members -- Antisense Approaches for Targeting BCL2 -- Natural Anti-apoptotic Compounds -- Small Molecule Inhibitors of BCL2 Family Members -- Novel BCL2 Inhibitors on the Horizon -- Mechanisms of Resistance to BCL2 Inhibitors -- Novel Mechanisms to Overcome BCL2 Resistance -- Targeting MCL1 -- PROTAC Strategies for Targeting Apoptotic Family Members -- Conclusions -- Must Read References -- References -- 12 Clinical Experience with Pro-Apoptotic Agents -- Take Home Messages -- Introduction. Safety and Toxicities of Pro-apoptotic Agents -- Tumor Lysis Syndrome -- Myeloid Compartment Toxicities and Infections -- Gastrointestinal Toxicities -- Thrombocytopenia and Navitoclax -- Efficacy of Venetoclax in Chronic Lymphocytic Leukemia/Small Cell Lymphoma -- Phase 1/2 Studies -- Combining Venetoclax with Conventional Chemotherapy in CLL/SLL -- Phase 3 Studies -- Venetoclax Re-treatment -- Efficacy of Venetoclax in Other B-cell Neoplasms -- Mantle Cell Lymphoma -- Follicular Lymphoma -- Diffuse Large B-cell Lymphoma and Other Aggressive B-cell Lymphomas -- Richter Transformation -- Waldenstrom's Macroglobulinemia -- Marginal Zone Lymphoma -- Acute Lymphoblastic Leukemia/Lymphoma -- Lessons from Venetoclax in Lymphoid Neoplasms Other than CLL/SLL -- Associations and Mechanisms of Resistance to Pro-apoptotic Agents -- Must Read References -- References -- 13 Promising Combinations of Drugs Targeting Apoptosis -- Take Home Messages -- Introduction: Background and Disease Perspective -- Clinical Development of BCL2 Inhibitors -- Venetoclax Monotherapy for CLL -- Venetoclax Plus CD20 Monoclonal Antibody for CLL -- Venetoclax Plus BTK Inhibitor for CLL -- Venetoclax Plus BTK Inhibitor and CD20 Monoclonal Antibody for CLL -- Venetoclax Plus Chemoimmunotherapy -- Venetoclax Toxicities and Side Effects in CLL -- TLS Risk Mitigation and Management in CLL -- Venetoclax-associated Neutropenia -- Risk for Progression and Resistance Mechanisms -- Current Knowledge Gaps and Opportunities for Future Work with Venetoclax -- Must Read References -- References -- Section IV Targeting the Cancer Epigenome -- 14 The Role of Epigenetic Dysregulation in Lymphoma Biology -- Take Home Messages -- Introduction: Germinal Center B (GCB)-cells and GCB-derived Lymphomas -- Mutations Altering DNA Modifications and Structure -- TET2. Mutations Altering Writers of Histone Post-translational Modifications. |
| Record Nr. | UNINA-9910830571103321 |
| Hoboken, New Jersey : , : John Wiley & Sons, Inc., , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
